The Kissick Family Foundation Frontotemporal Dementia (FTD) Grant Program will fund a second cohort of research to understand the fundamental biology of why and how sporadic forms of FTD develop. In partnership with the Milken Institute Science Philanthropy Accelerator for Research and Collaboration (SPARC), the program seeks to broaden the foundational knowledge of FTD to spur diagnostic and therapeutic advancements. SPARC is now accepting applications for two-year projects to conduct basic or early-stage translational research on this topic.
About the Request for Proposals (RFP)
The Kissick Family Foundation Frontotemporal Dementia Grant Program intends to award up to five two-year research grants led by doctoral-level investigators at qualifying research-based institutions worldwide. Projects will be eligible for up to $500,000 in funding over two years, inclusive of indirect costs.
Please download the RFP for further details.
To be eligible for this opportunity, a one-page Letter of Intent is due by Friday, November 1, 2024. Full proposals for selected applicants are due February 7, 2025. All materials should be submitted on this page through the program's SurveyMonkey Apply portal.
To learn more about this opportunity, researchers are invited to join an informational webinar on Tuesday, October 15, 2024, at 11 a.m. EST. A registration link for the webinar can be found here.
About FTD
Frontotemporal dementia (FTD) is a family of neurodegenerative conditions that cause changes in behavior, mood, executive function, language, memory, and motor function. Based on brain pathology, FTD could account for as many as 10-20% of all dementia cases. The disease is underdiagnosed, and a true global prevalence estimate is hindered by a general lack of awareness and the complex nature of its detection. The hallmark trait of FTD is a progressive deterioration of the brain’s frontal and temporal lobes, but clear biomarkers or FTD-specific treatments have not been developed. Research into FTD linked to the known autosomal dominant genetic variants GRN, MAPT, and C9orf drives most of the current scientific development. Yet only about 25-30% of patients have identified genetic causes, pointing to the need for targeted research to understand sporadic FTD that occurs outside of the autosomal dominant forms.
Kissick Family Foundation Frontotemporal Dementia Grant Program
The Kissick Family Foundation Frontotemporal Dementia (FTD) Grant Program will fund a second cohort of research to understand the fundamental biology of why and how sporadic forms of FTD develop. In partnership with the Milken Institute Science Philanthropy Accelerator for Research and Collaboration (SPARC), the program seeks to broaden the foundational knowledge of FTD to spur diagnostic and therapeutic advancements. SPARC is now accepting applications for two-year projects to conduct basic or early-stage translational research on this topic.
About the Request for Proposals (RFP)
The Kissick Family Foundation Frontotemporal Dementia Grant Program intends to award up to five two-year research grants led by doctoral-level investigators at qualifying research-based institutions worldwide. Projects will be eligible for up to $500,000 in funding over two years, inclusive of indirect costs.
Please download the RFP for further details.
To be eligible for this opportunity, a one-page Letter of Intent is due by Friday, November 1, 2024. Full proposals for selected applicants are due February 7, 2025. All materials should be submitted on this page through the program's SurveyMonkey Apply portal.
To learn more about this opportunity, researchers are invited to join an informational webinar on Tuesday, October 15, 2024, at 11 a.m. EST. A registration link for the webinar can be found here.
About FTD
Frontotemporal dementia (FTD) is a family of neurodegenerative conditions that cause changes in behavior, mood, executive function, language, memory, and motor function. Based on brain pathology, FTD could account for as many as 10-20% of all dementia cases. The disease is underdiagnosed, and a true global prevalence estimate is hindered by a general lack of awareness and the complex nature of its detection. The hallmark trait of FTD is a progressive deterioration of the brain’s frontal and temporal lobes, but clear biomarkers or FTD-specific treatments have not been developed. Research into FTD linked to the known autosomal dominant genetic variants GRN, MAPT, and C9orf drives most of the current scientific development. Yet only about 25-30% of patients have identified genetic causes, pointing to the need for targeted research to understand sporadic FTD that occurs outside of the autosomal dominant forms.